Eli Lilly and Company (LLY)vsTivic Health Systems Inc (TIVC)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
TIVC
Tivic Health Systems Inc
$0.76
+1.33%
HEALTHCARE · Cap: $3.83M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 14989319% more annual revenue ($72.25B vs $482,000). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TIVC
Hold37
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
15.9% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : TIVC
The strongest argument for TIVC centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : TIVC
The primary concerns for TIVC are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
TIVC carries more volatility with a beta of 1.84 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 37/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Tivic Health Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Tivic Health Systems Inc (TIVC) is a pioneering medical technology firm focused on developing non-invasive bioelectronic therapies aimed at addressing chronic conditions, particularly allergic rhinitis. Leveraging its proprietary platform and extensive clinical expertise, Tivic Health is committed to delivering innovative solutions that not only meet critical patient needs but also optimize healthcare delivery. Positioned at the vanguard of the burgeoning bioelectronic medicine landscape, the company is set to seize emerging market opportunities, significantly improving patient outcomes and establishing new benchmarks in chronic condition management.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?